Anuh Pharma Board Meet on Feb 6, 2026: Q3 Results

Board meeting date and agenda

Anuh Pharma Ltd informed BSE that its Board of Directors is scheduled to meet on February 6, 2026. The company said the meeting is convened, among other matters, to consider and approve unaudited financial results. The filing headline referenced results for the quarter ended December 31, 2025. The intimation also mentioned consideration of unaudited financial results along with a limited review report for the quarter and half year ended September 30, 2025, and adoption of related items.

For investors, such board meeting intimations matter because they provide a clear date for when the next set of financial disclosures could be approved. For companies listed in India, these disclosures typically feed into near-term market focus on quarterly performance, margins, and cash flows. The announcement also comes after the company’s earlier FY25 corporate actions, including a bonus issue and a proposed final dividend.

What the company has communicated to the exchange

The exchange intimation is a standard compliance disclosure, but it provides two important anchors: timing and the nature of approvals. First, it puts a specific date on when the board will consider the unaudited results and the limited review report. Second, it signals that the results are expected to be placed before the board, which is a key step before they are published to the market.

The company did not provide the financial numbers for the December 2025 quarter in the intimation text shared here. As a result, the market’s immediate takeaway is the schedule itself rather than the performance details. Investors typically track these dates to plan around potential price volatility after results and to watch for any additional board decisions on capital allocation.

Recent corporate actions: bonus and dividend

Anuh Pharma’s recent corporate actions include a bonus issue and a final dividend proposal for FY2024-25. The company disclosed that the Board of Directors considered and approved an issue of bonus equity shares in the ratio 1:1. That means shareholders would receive 1 equity share of face value Rs 5 for every 1 fully paid-up equity share held, subject to shareholders’ approval through postal ballot. The record date for the bonus issue was to be announced separately.

On dividends, the board recommended a final dividend of Rs 1.50 per equity share on post-bonus share capital. The company described this as a 30% payout on the face value of Rs 5 each for FY2024-25, subject to shareholders’ approval at the AGM. It also stated that bonus shares would be entitled to the proposed final dividend of Rs 1.50 per share.

In the corporate actions table provided, the dividend (Rs 1.50 per share) carried an ex-date of August 14, 2025, and the bonus issue (1:1) carried an ex-date of July 15, 2025. The record date for the dividend was revised to Friday, August 15, 2025, as per a BSE announcement dated July 29, 2025.

Timeline of disclosed events

Financial snapshot: quarterly and annual performance already disclosed

The article text also carried financial performance details for FY25, including Q4 FY25 and full-year numbers. For the March 2025 quarter, Anuh Pharma reported sales (revenue from operations) of Rs 198.14 crore, up 20.90% from Rs 163.89 crore in the year-ago quarter. On a quarter-on-quarter basis, revenue rose 24.22% from Rs 159.51 crore in Q3 FY25.

Profitability metrics were mixed in the same period. EBITDA for Q4 FY25 was Rs 20.07 crore, down 8.98% from Rs 22.05 crore in Q4 FY24, while it increased 27.67% from Rs 15.72 crore in Q3 FY25. Net profit for Q4 FY25 declined 18.88% year-on-year to Rs 12.46 crore from Rs 15.36 crore in Q4 FY24.

For the full year ended March 2025, sales increased 2.24% to Rs 661.51 crore from Rs 647.00 crore in FY24. Net profit declined 21.16% to Rs 47.35 crore from Rs 60.06 crore in FY24.

Results table (normalised to Rs crore)

The exchange-style quarterly table shared in the prompt was reported in lakhs. Below is the same data converted to Rs crore for consistency (1 crore = 100 lakhs).

Other disclosures: assets and management

Alongside audited results for the year ended March 31, 2025, the company reported total assets of Rs 506.63 crore as of March 31, 2025 (reported as Rs 50,662.77 lakh). The board also approved the re-appointment of Mr. Ritesh Bipin Shah (DIN: 02496729) as Joint Managing Director, as stated in the filing extract.

These governance and balance sheet disclosures are typically read alongside profit-and-loss performance. Assets growth can reflect changes in working capital, capex, inventory, receivables, or other balance sheet items, though the specific drivers were not detailed in the text provided.

Market reaction and technical commentary

The prompt noted that Anuh Pharma shares rose about 3% after the company reported its March quarter result, along with a 30% dividend and the 1:1 bonus announcement. Separately, independent research analyst A R Ramachandran was quoted as saying the stock price was bullish but overbought on daily charts, with support at 180. The same comment referenced resistance at 217 and a near-term target of 244 if the stock closes above the resistance level.

Such technical views are market commentary and not company guidance. Investors generally weigh them against fundamentals, liquidity, and upcoming events such as board meetings and results announcements.

Why the February 2026 board date matters

With the February 6, 2026 board meeting date on record, investors have a clear marker for when Anuh Pharma’s next unaudited results could be approved and released. This becomes more relevant when set against the company’s recent quarter-to-quarter variability, where revenue growth was strong in Q4 FY25 while profits declined year-on-year. The market also continues to track the follow-through on corporate actions already announced, especially because both the bonus issue and the proposed final dividend were subject to shareholder approvals and procedural timelines.

Conclusion

Anuh Pharma’s BSE intimation sets February 6, 2026 as the board date to consider unaudited financial results, with the filing referencing the quarter ended December 31, 2025. The company has also recently disclosed a 1:1 bonus proposal and a final dividend recommendation of Rs 1.50 per share for FY2024-25, alongside FY25 audited results. The next key update, based on the information provided, will be the outcome of the February 2026 board meeting and any subsequent exchange filing of the approved results.